SOCRA Audits, Monitoring, and Inspections 3 — Questions and Answers
Question 1: Which ICH E6(R2) principle specifically addresses the need for a systematic, independent examination of trial-related activities to evaluate whether they were conducted according to the protocol?
- Risk management
- Audit (Correct answer)
- Inspection
- Quality assurance
Correct answer: Audit
ICH E6(R2) defines an audit as a systematic, independent examination to determine whether trial activities comply with the protocol, SOPs, GCP, and regulatory requirements.
Question 2: A sponsor is implementing Risk-Based Monitoring (RBM). Which factor would MOST likely increase the frequency of on-site monitoring for a particular site?
- The site has enrolled fewer than average subjects
- The site has a consistently low query rate
- The site has a high rate of protocol deviations and late adverse event reporting (Correct answer)
- The PI has more than 10 years of clinical trial experience
Correct answer: The site has a high rate of protocol deviations and late adverse event reporting
High protocol deviation rates and late SAE reporting are risk signals that indicate the site needs more intensive on-site oversight.
Question 3: During source data verification (SDV), the CRA finds that a lab value recorded in the CRF is different from the value in the laboratory report. This is an example of:
- A protocol deviation
- A data discrepancy requiring a query (Correct answer)
- An adverse event
- A serious breach
Correct answer: A data discrepancy requiring a query
A transcription error between source data and the CRF is a data discrepancy that should be resolved through the query process.
Question 4: When an FDA inspector issues a Form FDA 483, what does this document represent?
- A formal warning letter requiring immediate corrective action
- Inspectional observations of conditions that may constitute violations (Correct answer)
- A notice that the trial has been placed on clinical hold
- Approval of the site's corrective action plan
Correct answer: Inspectional observations of conditions that may constitute violations
FDA 483 lists observations of conditions the inspector believes may violate regulations; it is not a final agency determination and gives the inspected party an opportunity to respond.
Question 5: A CRA is conducting centralized (remote) monitoring and notices that a site has an unusually low screen failure rate compared to all other sites. This pattern should trigger:
- An immediate protocol amendment
- A data query to the site about their screening process
- A risk signal investigation that may prompt a for-cause audit (Correct answer)
- IRB notification within 24 hours
Correct answer: A risk signal investigation that may prompt a for-cause audit
Outlier patterns in key metrics like screen failure rates can indicate data fabrication or inappropriate enrollment, warranting further investigation and potentially a for-cause audit.
Question 6: According to ICH E6(R2), the sponsor's audit function must be independent of:
- The IRB and ethics committee
- Clinical monitoring and trial management (Correct answer)
- The regulatory affairs department
- The data management team
Correct answer: Clinical monitoring and trial management
ICH E6(R2) requires that auditors be independent of clinical monitoring and trial management to provide an objective assessment of quality.
Question 7: What is 'source data' as defined under ICH E6(R2)?
- Only electronic records generated by laboratory equipment
- All information in original records and certified copies used to reconstruct and evaluate the trial (Correct answer)
- The CRF data entered by the site coordinator
- Sponsor-held regulatory documents
Correct answer: All information in original records and certified copies used to reconstruct and evaluate the trial
Source data includes all original records (paper or electronic) and certified copies from which CRF data are derived, enabling reconstruction and evaluation of the trial.
SOCRA Audits, Monitoring, and Inspections 3
Which ICH E6(R2) principle specifically addresses the need for a systematic, independent examination of trial-related activities to evaluate whether they were conducted according to the protocol?